Michael Armanyous

University of Toronto - University Health Network

101 College Street

Toronto, ON M5G 1L7

Canada

SCHOLARLY PAPERS

1

DOWNLOADS

179

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Clinical Trial

Number of pages: 33 Posted: 05 Mar 2025
University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Toronto - University Health Network, University of Barcelona - Institute of Neuroscience, University of Toronto - University Health Network, University of Toronto - Mood Disorders Psychopharmacology Unit and University of Toronto - University Health Network
Downloads 179 (360,370)

Abstract:

Loading...

major depressive disorder, glucagon-like peptide 1 receptor agonist, semaglutide, cognitive function, randomised clinical trial